Latest news and press releases about BillionToOne, Inc. (BLLN): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
BillionToOne, Inc. is a specialized diagnostics company that innovates by precisely quantifying biological data to create advanced molecular diagnostic solutions. Central to their operations is a cutting-edge molecular counting platform, meticulously engineered to identify and measure individual DNA molecules, thereby significantly enhancing the precision of disease detection.
Price
| Price | $105.90 |
| Market Cap | $4.9B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| P/E Ratio | 170.78 |
| Price / Book | 9.15 |
| EV / EBITDA | 88.89 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 7.87% |
| Return on Invested Capital | 6.33% |
| Return on Assets | 4.59% |
| Gross Margin | 71.27% |
| Operating Margin | 10.90% |
| Net Margin | 8.43% |
Explore sector: Healthcare · Medical - Diagnostics & Research
More sections of BLLN: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks